Stock Price & Analysis

Based on strong fundamentals and analyst optimism, BDX is a buy. However, consider waiting for technical indicators to stabilize before entering.

Price Prediction for BDX Stock in 2025

Becton Dickinson (BDX) stock is expected to reach a price target of $270-$278 in 2025.
The prediction is supported by strong Q1 2025 earnings, with revenue up 9.8% and adjusted EPS up 28% year-over-year. Analysts maintain a "Strong Buy" consensus with a mean price target of $273.47.

The S1 support level for BDX Stock is $226.02 ,The R1 resistant level for BDX Stock is $232.43.

As of the end of day on 2025-04-01, the price of BDX Stock was $227.69.

The target price for BDX Stock according to analyst rating is 274.00, with the highest price target at 280.00 and the lowest at 260.00. Analysts have a Strong Buy rating on BDX Stock overall.

The market cap of BDX is $64.9B.

Analysis and Insights

To determine if Becton Dickinson and Co (BDX) is overvalued, we analyze its valuation metrics, financial performance, and market sentiment.

Valuation Metrics:

• PE Ratio: BDX's PE ratio has decreased from 54.88 in Q2 2024 to 38.21 in Q1 2025, indicating improving earnings or a stock price decline.
• EV/EBITDA: The ratio dropped from 16.79 to 15.91, suggesting a more reasonable valuation.
• PS Ratio: Declined from 3.65 to 3.19, indicating the stock may be undervalued relative to revenue.
• PB Ratio: Decreased from 2.80 to 2.58, suggesting the stock might be undervalued compared to book value.
• Dividend Yield: Increased slightly to 1.71%, enhancing appeal for income investors.

Financial Performance:

• Revenue: Fluctuated but showed a slight increase in Q1 2025.
• Net Income: Inconsistent, with a significant drop in Q4 2024.
• Gross Profit: Stable, a positive sign.
• ROE & Net Margin: Both decreased, indicating potential profitability issues.

Market Sentiment:

• Analyst Ratings: BDX received a 91% rating from Validea's P/E/Growth Investor model, highlighting strong fundamentals.
• Stock Reaction: Fell 7.3% post-earnings despite strong Q1 results, due to macroeconomic concerns.
• Analyst Consensus: "Strong Buy" with a mean price target of $273.47, indicating optimism.

Technical Analysis:

• Trend: Trading below 50-day and 200-day moving averages, a bearish signal.
• RSI: Around 52, neutral, but near lower Bollinger Band, suggesting potential undervaluation.

Conclusion:

While BDX isn't significantly overvalued, the market may be pricing in future growth. Investors should weigh the company's fundamentals and market sentiment.

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Becton Dickinson and Co (BDX) is expected to reach a stock price of $350 by 2030, driven by its strong fundamentals, strategic restructuring, and positive analyst sentiment. The company's planned separation of its Biosciences and Diagnostic Solutions business aims to enhance focus and drive growth, supporting long-term value creation. Analysts maintain a "Strong Buy" consensus with a mean price target of $273.47, reflecting optimism in its future prospects.

BDX has a total of 73000 employees.